Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Stroke Cerebrovasc Dis ; 29(3): 104531, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31882337

ABSTRACT

BACKGROUND: The purpose of this study was to investigate the effects of edaravone on nitric oxide (NO) production, hydroxyl radical (OH-) metabolism, and neuronal nitric oxide synthase (nNOS) expression during cerebral ischemia and reperfusion. METHODS: Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion. Eleven additional mice received saline (controls). NO production and OH- metabolism were continuously monitored using bilateral striatal in vivo microdialysis. OH- formation was monitored using the salicylate trapping method. Forebrain ischemia was produced in all mice by bilateral occlusion of the common carotid artery for 10 minutes. Levels of NO metabolites, nitrite (NO2-) and nitrate (NO3-), were determined using the Griess reaction. Brain sections were immunostained with an anti-nNOS antibody and the fractional area density of nNOS-immunoreactive pixels to total pixels determined. RESULTS: Blood pressure and regional cerebral blood flow were not significantly different between the edaravone and control groups. The levels of NO2- did not differ significantly between the 2 groups. The level of NO3- was significantly higher in the edaravone group compared with the control group after reperfusion. 2,3-dihydroxybenzoic acid levels were lower in the edaravone group compared with those in the control group after reperfusion. Immunohistochemistry showed nNOS expression in the edaravone group to be significantly lower than that in the control group 96 hours after reperfusion. CONCLUSIONS: These in vivo data indicate that edaravone may have a neuroprotective effect by reducing levels of OH- metabolites, increasing NO production and decreasing nNOS expression in brain cells.


Subject(s)
Brain Ischemia/drug therapy , Brain/drug effects , Edaravone/pharmacology , Free Radical Scavengers/pharmacology , Hydroxyl Radical/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide/metabolism , Reperfusion Injury/prevention & control , Animals , Brain/enzymology , Brain/pathology , Brain Ischemia/enzymology , Brain Ischemia/pathology , Disease Models, Animal , Mice, Inbred C57BL , Neurons/enzymology , Neurons/pathology , Reperfusion Injury/enzymology , Reperfusion Injury/pathology , Time Factors
2.
J Stroke Cerebrovasc Dis ; 28(5): 1151-1159, 2019 May.
Article in English | MEDLINE | ID: mdl-30655039

ABSTRACT

BACKGROUND: The purpose of this study was to investigate the effects of yokukansan on forebrain ischemia. Because we can measure nitric oxide production and hydroxyl radical metabolism continuously, we investigated the effect of yokukansan on nitric oxide production and hydroxyl radical metabolism in cerebral ischemia and reperfusion. METHODS: Yokukansan (300 mg per kg per day) was mixed into feed and given to 16 mice for 10days. Sixteen additional mice received normal feed (control). Nitric oxide production and hydroxyl radical metabolism were continuously monitored using the salicylate trapping method. Forebrain ischemia was producedin all mice by occluding the common carotid artery bilaterally for 10minutes. Levels of the nitric oxide metabolites nitrite and nitrate were determined using the Griess reaction. Survival rates of hippocampal CA1 neurons were calculated and 8-hydroxydeoxyguanosine-immunopositive cells were counted to evaluate the oxidative stress in hippocampal CA1 neurons 72hours after the start of reperfusion. RESULTS: Arterial blood pressure and regional cerebral blood flow were not significantly different between the 2 groups. The level of nitrate was significantly higher in the yokukansan group than in the control group during ischemia and reperfusion. Levels of 2,3- and 2,5-dihydroxybenzoic acid were significantly lower in the yokukansan group than in the control group during ischemia and reperfusion. Although survival rates in the CA1 did not differ significantly, there were fewer 8-hydroxydeoxyguanosine-immunopositive cells in animals that had received yokukansan than in control animals. CONCLUSIONS: These data suggest that yokukansan exerts reducing hydroxyl radicals in cerebral ischemic injury.


Subject(s)
Antioxidants/pharmacology , Brain Ischemia/drug therapy , CA1 Region, Hippocampal/drug effects , Drugs, Chinese Herbal/pharmacology , Hydroxyl Radical/metabolism , Neuroprotective Agents/pharmacology , Nitric Oxide/metabolism , Reperfusion Injury/prevention & control , Animals , Brain Ischemia/metabolism , Brain Ischemia/pathology , CA1 Region, Hippocampal/metabolism , CA1 Region, Hippocampal/pathology , Disease Models, Animal , Mice, Inbred C57BL , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Oxidative Stress/drug effects , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Time Factors
3.
J Stroke Cerebrovasc Dis ; 27(6): 1609-1615, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29426680

ABSTRACT

BACKGROUND: The purpose of this study was to investigate the effects of memantine on brain ischemia. Because we can measure nitric oxide (NO) production and hydroxyl radical metabolism continuously, we investigated the effect of memantine on NO production and hydroxyl radical metabolism in cerebral ischemia and reperfusion. METHODS: Memantine (25 µmol/kg) was administered intraperitoneally to 6 C57BL/6 mice 30 minutes before ischemia. Seven additional mice received no injection (controls). NO production and hydroxyl radical metabolism were continuously monitored using bilateral striatal microdialysis in vivo. Hydroxyl radical formation was monitored using the salicylate trapping method. Forebrain ischemia was produced in all mice by occluding the common carotid artery bilaterally for 10 minutes. Levels of the NO metabolites nitrite (NO2-) and nitrate (NO3-) were determined using the Griess reaction. Survival rates of hippocampal CA1 neurons were calculated and 8-hydroxydeoxyguanosine (8-OHdG)-immunopositive cells were counted to evaluate the oxidative stress in hippocampal CA1 neurons 72 hours after the start of reperfusion. RESULTS: The regional cerebral blood flow was significantly higher in the memantine group than in the control group after reperfusion. Furthermore, the level of 2,3-dihydroxybenzoic acid was significantly lower in the memantine group than in the control group during ischemia and reperfusion. Levels of NO2- and NO3- did not differ significantly between the 2 groups. Although survival rates in the CA1 did not differ significantly, there were fewer 8-OHdG-immunopositive cells in animals that had received memantine than in control animals. CONCLUSIONS: These data suggest that memantine exerts partially neuroprotective effects against cerebral ischemic injury.


Subject(s)
Antioxidants/pharmacology , Brain Ischemia/prevention & control , CA1 Region, Hippocampal/drug effects , Hydroxyl Radical/metabolism , Memantine/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Reperfusion Injury/prevention & control , Animals , Biomarkers/metabolism , Blood Flow Velocity , Brain Ischemia/metabolism , Brain Ischemia/pathology , Brain Ischemia/physiopathology , CA1 Region, Hippocampal/blood supply , CA1 Region, Hippocampal/metabolism , CA1 Region, Hippocampal/pathology , Cerebrovascular Circulation/drug effects , Cytoprotection , Disease Models, Animal , Mice, Inbred C57BL , Microdialysis , Neurons/metabolism , Neurons/pathology , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Time Factors
4.
Int Immunol ; 22(5): 375-86, 2010 May.
Article in English | MEDLINE | ID: mdl-20215335

ABSTRACT

Zinc (Zn) is an essential trace metal required by many enzymes and transcription factors for their activity or the maintenance of their structure. Zn has a variety of effects in the immune responses and inflammation, although it has not been well known how Zn affects these reactions on the molecular basis. We here showed that Zn suppresses T(h)17-mediated autoimmune diseases at lest in part by inhibiting the development of T(h)17 cells via attenuating STAT3 activation. In mice injected with type II collagen to induce arthritis, Zn treatment inhibited T(h)17 cell development. IL-6-mediated activation of STAT3 and in vitro T(h)17 cell development were all suppressed by Zn. Importantly, Zn binding changed the alpha-helical secondary structure of STAT3, disrupting the association of STAT3 with JAK2 kinase and with a phospho-peptide that included a STAT3-binding motif from the IL-6 signal transducer gp130. Thus, we conclude that Zn suppresses STAT3 activation, which is a critical step for T(h)17 development.


Subject(s)
Arthritis, Experimental/drug therapy , Interleukin-17/immunology , STAT3 Transcription Factor/antagonists & inhibitors , Th17 Cells/drug effects , Th17 Cells/immunology , Zinc/pharmacology , Animals , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Cells, Cultured , Humans , Mice , Mice, Inbred C57BL , STAT3 Transcription Factor/metabolism , Structure-Activity Relationship , Th17 Cells/cytology , Th17 Cells/metabolism
5.
Immunity ; 30(3): 447-57, 2009 Mar 20.
Article in English | MEDLINE | ID: mdl-19285437

ABSTRACT

Systemic cytokine activity in response to Toll-like receptor (TLR) signaling induces the expression of various proteins in the liver after infections. Here we show that Interleukin-7 (IL-7), the production of which was thought to occur at a constant rate in vivo, was a hepatically expressed protein that directly controled T cell responses. Depletion of IL-7 expression in the liver abrogated several TLR-mediated T cell events, including enhanced CD4+ T cell and CD8+ T cell survival, augmented CD8+ T cell cytotoxic activity, and the development of experimental autoimmune encephalitis, a Th17 cell-mediated autoimmune disease. Thus, T cell responses are regulated by hepatocyte-derived IL-7, which is expressed in response to TLR signaling in vivo. We suggested that TLR-induced IL-7 expression in the liver, which is an acute-phase response, may be a good diagnostic and therapeutic target for efficient vaccine developments and for conditions characterized by TLR-mediated T cell dysregulation, including autoimmune diseases.


Subject(s)
Interleukin-7/metabolism , Liver/immunology , T-Lymphocytes/immunology , Animals , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Gene Expression Regulation/drug effects , Hepatocytes/immunology , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred C57BL , Polymerase Chain Reaction
6.
Immunity ; 29(4): 628-36, 2008 Oct 17.
Article in English | MEDLINE | ID: mdl-18848474

ABSTRACT

Dysregulated cytokine expression and signaling are major contributors to a number of autoimmune diseases. Interleukin-17A (IL-17A) and IL-6 are important in many disorders characterized by immune self-recognition, and IL-6 is known to induce the differentiation of T helper 17 (Th17) cells. Here we described an IL-17A-triggered positive-feedback loop of IL-6 signaling, which involved the activation of the transcription factors nuclear factor (NF)-kappaB and signal transducer and activator of transcription 3 (STAT3) in fibroblasts. Importantly, enhancement of this loop caused by disruption of suppressor of cytokine signaling 3 (SOCS3)-dependent negative regulation of the IL-6 signal transducer gp130 contributed to the development of arthritis. Because this mechanism also enhanced experimental autoimmune encephalomyelitis (EAE) in wild-type mice, it may be a general etiologic process underlying other Th17 cell-mediated autoimmune diseases.


Subject(s)
Autoimmunity , Fibroblasts/immunology , Interleukin-6/metabolism , STAT3 Transcription Factor/metabolism , Suppressor of Cytokine Signaling Proteins/metabolism , Animals , Arthritis/immunology , Arthritis/metabolism , Cytokine Receptor gp130/immunology , Cytokine Receptor gp130/metabolism , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Feedback, Physiological , Fibroblasts/metabolism , Interleukin-17/immunology , Interleukin-17/metabolism , Interleukin-6/immunology , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , NF-kappa B/metabolism , Signal Transduction , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins/immunology
7.
Int Immunol ; 19(6): 695-702, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17493959

ABSTRACT

IL-17-producing Th (Th17) comprise a distinct lineage of pro-inflammatory Th that are major contributors to autoimmune diseases. Treatment with IL-6 and transforming growth factor beta (TGFbeta) induces naive CD4+ T cells to generate Th17, which also requires expression of the IL-6/TGFbeta target RORgammat. We reported that IL-6 transduces two signaling pathways via tyrosine redidues of the signal transducer gp130: one depends on signal transducers and activators of transcription (STAT)-3 activation and the other on Src homology region 2 domain-containing phosphatase 2 (SHP2)/Grb2 associated binder (Gab)/mitogen-activated protein kinase (MAPK) activation. Here, we showed that CD4+ T cells carrying a mutant gp130 that transduces the SHP2/Gab/MAPK pathway but not the STAT3-mediated one failed to develop into Th17, while CD4+ T cells whose mutant gp130 transduces the STAT3 signal only generated Th17, indicating that IL-6 acts directly on T cells through the tyrosine residues of gp130 required for STAT3 activation to promote the development of Th17. Moreover, we found that gp130-STAT3 pathway is essential for Th17 development and for the expression of RORgammat by using T cells specifically lacking gp130 and STAT3. Noteworthy is that the regulatory T cell (Treg) percentages and numbers were comparable between all mutant mice we tested in vivo, although we showed that IL-6-gp130-STAT3 pathway suppressed Treg development in vitro. Thus, we conclude that IL-6 acts directly to promote the development of Th17 by activating the T cell gp130-STAT3 pathway but has a minimum effect on Treg development at least in the steady state in vivo. Therefore, blockade of IL-6-gp130-STAT3 pathway in CD4+ T cells could be a good target for controlling unwanted Th17-mediated immune responses including autoimmune diseases.


Subject(s)
Cytokine Receptor gp130/physiology , Interleukin-17/metabolism , Interleukin-6/physiology , STAT3 Transcription Factor/physiology , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Arthritis, Experimental/blood , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Cell Count , Cell Differentiation/drug effects , Cell Differentiation/immunology , Cytokine Receptor gp130/genetics , Flow Cytometry , Forkhead Transcription Factors/metabolism , Interleukin-17/blood , Interleukin-17/immunology , Interleukin-6/genetics , Interleukin-6/pharmacology , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Mice, Transgenic , Nuclear Receptor Subfamily 1, Group F, Member 3 , Receptors, Retinoic Acid/metabolism , Receptors, Thyroid Hormone/metabolism , STAT3 Transcription Factor/genetics , Signal Transduction/drug effects , Signal Transduction/immunology , Spleen/cytology , Spleen/immunology , T-Lymphocytes, Helper-Inducer/cytology , T-Lymphocytes, Helper-Inducer/metabolism , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/metabolism
8.
J Clin Invest ; 117(5): 1270-81, 2007 May.
Article in English | MEDLINE | ID: mdl-17476359

ABSTRACT

Patients with Omenn syndrome (OS) have hypomorphic RAG mutations and develop varying manifestations of severe combined immunodeficiency. It is not known which symptoms are caused directly by the RAG mutations and which depend on other polymorphic genes. Our current understanding of OS is limited by the lack of an animal model. In the present study, we identified a C57BL/10 mouse with a spontaneous mutation in, and reduced activity of, RAG1. Mice bred from this animal contained high numbers of memory-phenotype T cells and experienced hepatosplenomegaly and eosinophilia, had oligoclonal T cells, and demonstrated elevated levels of IgE, major symptoms of OS. Depletion of CD4+ T cells in the mice caused a reduction in their IgE levels. Hence these "memory mutant" mice are a model for human OS; many symptoms of their disease were direct results of the Rag hypomorphism and some were caused by malfunctions of their CD4+ T cells.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , Cell Proliferation , Disease Models, Animal , Homeostasis/immunology , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/pathology , Animals , Female , Gene Deletion , Homeostasis/genetics , Humans , Immunologic Deficiency Syndromes/genetics , Immunologic Memory/genetics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred NZB , Mice, Knockout
SELECTION OF CITATIONS
SEARCH DETAIL
...